Entries by CURC

A New Sustained-Release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer

/in /by

Neal D. Shore, MD1; Sílvia Guerrero, PhD2; Rosa Ma Sanahuja, MS2;Gemma Gambús, MD, PhD2; and Antonio Parente, PhD2 Purpose: This clinical trial investigated the effectiveness, pharmacokinetic properties, and safety profile of leuprolide acetate 22.5-mg depot, a new 3-month leuprolide depot formulation, as androgen deprivation therapy for patients with prostate cancer. Click here to read more

Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

/in /by

Background Prostate‐specific membrane antigen (PSMA) is a well‐characterized target that is overexpressed selectively on prostate cancer cells. PSMA antibody‐drug conjugate (ADC) is a fully human IgG1 monoclonal antibody conjugated to the microtubule disrupting agent monomethyl auristatin E (MMAE), which is designed to specifically bind PSMA‐positive cells, internalize, and then release its cytotoxic payload into the […]

Managing the Adverse Effects of Drug Treatments for Advanced Prostate Cancer

/in /by

Ask The Experts: Neal D. Shore, MD Practice Community: Myrtle Beach, South Carolina Hospital and Institutional Affiliations: Director, CPI, Carolina Urologic Research Center, Myrtle Beach, South Carolina, and President of the Large Urology Group Practice Association Number of Patients Seen in a Week: 150 Practice Niche: Urologic Oncology click here to read entire Q&A

LUGPA president details decade of successes with eye on future

/in /by

Chicago—A decade since its founding, LUGPA is looking to the future with ambitious goals aimed at sustaining and strengthening the practice of independent urology. That was the message of LUGPA President Neal D. Shore, MD, at the association’s 10thanniversary meeting in Chicago. Dr. Shore detailed 10 years of successes that span LUGPA’s initiatives in advocacy, […]

The PROSPER Trial: Chemotherapy-Related Endpoints in Patients with nmCRPC – Neal Shore

/in /by

Neal Shore, MD, FACS presents his 2018 AUA presentation on the groundbreaking PROSPER trial: chemotherapy-related endpoints in patients with nonmetastatic castration-resistant prostate cancer treated with enzalutamide. Meeting an unmet need in this Index 1 patient population with a goal of delaying time to metastasis has the potential to delay cancer-related morbidity and antineoplastic therapies and […]